Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
CAN, UNFI, SUNB, More
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Shake Shack (SHAK) at Outperform
- Rothschild Redburn Starts Tempus AI Inc (TEM) at Neutral
- JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
